TP53 and prostate carcinoma: Several laboratories have tested synthetic bile acid derivatives in MCF-7 human breast cancer cells (wild-type p53), MDA-MB-231 (mutant p53), PC-3 human prostate cancer cells (null-type p53), and HT-29 human colon cancer cells (mutant p53).